Moleculin Biotech (MBRX) has received Institutional Review Board – IRB – approval for its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine for the treatment of AML patients who are refractory to or relapsed after induction therapy. This Phase 3 “MIRACLE” trial will be a global trial, including sites in the US. The company believes enrollment will commence in Q1 2025. Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia, in addition to Orphan Drug Designation for the treatment of soft tissue sarcoma. Furthermore, Annamycin has Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia from the European Medicines Agency.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX: